Trial record 1 of 9 for:
NMD | Spinal Muscular Atrophy
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy (SYNAPSE-SMA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05794139 |
|
Recruitment Status :
Recruiting
First Posted : April 3, 2023
Last Update Posted : November 8, 2023
|
Sponsor:
NMD Pharma A/S
Information provided by (Responsible Party):
NMD Pharma A/S
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of NMD670 in the treatment of ambulatory adults with spinal muscular atrophy type 3
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Spinal Muscular Atrophy | Drug: NMD670 Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 54 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Intervention Model Description: | 2-way crossover |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomised, Double-blind, Placebo-controlled, 2-way Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 in Ambulatory Adults With Type 3 Spinal Muscular Atrophy |
| Actual Study Start Date : | September 21, 2023 |
| Estimated Primary Completion Date : | September 2024 |
| Estimated Study Completion Date : | September 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Spinal muscular atrophy
MedlinePlus related topics:
Spinal Muscular Atrophy
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
Experimental drug followed by placebo
|
Drug: NMD670
Tablets Drug: Placebo Tablets |
|
Experimental: Cohort 2
Placebo followed by experimental drug
|
Drug: NMD670
Tablets Drug: Placebo Tablets |
Primary Outcome Measures :
- Change from baseline in 6 minute walk test (6MWT) total distance versus placebo [ Time Frame: Baseline to day 21 ]Distance walked (meters)
Secondary Outcome Measures :
- Change from baseline in muscle strength versus placebo [ Time Frame: Baseline to day 21 ]Handgrip, knee flexor, elbow flexor, elbow extension and should abduction (Newton)
- Change from baseline in 6 minute walk test (6MWT) fatigue index versus placebo [ Time Frame: Baseline to day 21 ]percentage change in distance walked in 6th minute compared to 1st minute
- Change from baseline in Revised Hammersmith Scale (RHS) versus placebo [ Time Frame: Baseline to day 21 ]Total score. Scale goes from 0-69 and higher score indicates improvement of symptoms
- Change from baseline in time to dropout in the endurance shuttle 9-hole peg test (ESNHPT) versus placebo [ Time Frame: Baseline to day 21 ]time to dropout (seconds)
- Change from baseline in proportion of patients that drops out in the endurance shuttle 9-hole peg test (ESNHPT) versus placebo [ Time Frame: Baseline to day 21 ]Proportion of patient dropout (%)
- Change from baseline in jitter versus placebo [ Time Frame: Baseline to day 21 ]Jitter (micro seconds) assessed with single fiber EMG
- Change from baseline in blocking versus placebo [ Time Frame: Baseline to day 21 ]Blocking (%) assessed with single fiber EMG
- Incidence of treatment emergent adverse events [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of serious treatment emergent adverse events [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of clinically significant abnormalities on physical examinations [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of clinically significant abnormalities on safety laboratory parameters [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of clinically significant vital signs abnormalities [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of clinically significant ECG abnormalities [ Time Frame: Over 21 days of dosing ]Summarised per treatment
- Incidence of Suicidal Ideation or Suicidal Behavior [ Time Frame: Over 21 days of dosing ]Summarised per treatment
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participants who are with a clinical diagnosis of Type 3 SMA.
- Participants who are ambulatory, defined as being able to walk at least 50 metres without walking aids.
- Participant with genetic confirmation of diagnosis (i.e., homozygous deletion of survival of motor neuron 1 gene [SMN1]).
- Participant with 3 to 5 copies of survival of motor neuron 2 gene [SMN2].
- Participant has a body mass index (BMI) within the range 19-30 kg/m2 (inclusive).
- Participant is male or female.
- Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Participant is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
Exclusion Criteria:
- Participants with prior surgery or fixed deformity (scoliosis, contractures) which would restrict ability to perform study-related tasks.
- Participants with other significant disease that may interfere with the interpretation of study data (e.g., other neuromuscular or muscular diseases).
- Participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study
- Participants received treatment with an investigational medical product (IMP) within 30 days (or 5 half-lives of the medication, whichever is longer) prior to Day 1.
- Participants with history of poor compliance with relevant SMA therapy.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05794139
Contacts
| Contact: NMD Pharma A/S | contact@nmdpharma.com | contact@nmdpharma.com |
Locations
Show 18 study locations
Sponsors and Collaborators
NMD Pharma A/S
| Responsible Party: | NMD Pharma A/S |
| ClinicalTrials.gov Identifier: | NCT05794139 |
| Other Study ID Numbers: |
NMD670-02-0001 2022-002301-24 ( EudraCT Number ) |
| First Posted: | April 3, 2023 Key Record Dates |
| Last Update Posted: | November 8, 2023 |
| Last Verified: | November 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by NMD Pharma A/S:
|
Transmission Enhancer Neuromuscular Junction Transmission ClC-1 |
Additional relevant MeSH terms:
|
Muscular Atrophy Muscular Atrophy, Spinal Atrophy Spinal Cord Diseases Pathological Conditions, Anatomical Neuromuscular Manifestations |
Neurologic Manifestations Nervous System Diseases Central Nervous System Diseases Motor Neuron Disease Neurodegenerative Diseases Neuromuscular Diseases |